Gunderson Dettmer Advises City Therapeutics in $1 Billion Strategic Collaboration with Biogen to Advance RNAi Therapies

Gunderson Dettmer represented client City Therapeutics, a Cambridge-based biopharmaceutical company pioneering RNA interference (RNAi)-based medicine, in its $ 1 billion strategic collaboration with Biogen Inc., a company focused on pioneering innovative science to deliver new medicines. City Therapeutics will leverage its next-generation RNAi engineering technologies alongside Biogen’s proprietary drug delivery platform to develop novel RNAi therapies targeting central nervous system diseases. The collaboration will initially focus on a single disease target, with the potential to expand to additional programs.

In the announcement of the collaboration, CEO of City Therapeutics Andy Orth said, “Partnering with Biogen represents a meaningful milestone in our mission to expand the therapeutic reach of RNAi, as we pioneer the next generation of RNAi technology for breakthrough medicines. By combining our novel RNAi platform with Biogen’s industry-leading capabilities in global drug development, we aim to accelerate the advancement of therapies for serious diseases. We look forward to demonstrating the potential of our RNAi platform in addressing this area of significant unmet need.”

The Gunderson deal team was led by Brendan McCarthy and Shu Hu.

Companies
City Therapeutics
Biogen Inc.